Addiction Toxicology Case Conference - January 2026

Register
- Non-member - Tier I - Free!
- Non-member - Tier II - Free!
- Non-member - Tier III - Free!
- Non-member - Tier IV - Free!
- Member - Tier I - Free!
- Member - Tier II - Free!
- Member - Tier III - Free!
- Member - Tier IV - Free!
Continue

7-OH & Medetomidine and other Novel Substances Emerging Adulterants on the Drug Scene

Friday, January 9, 2026
1:00-2:00pm ET

Case 1: 27-year-old M spending $100-$200/day on 7-OH-mytraginine calls for help with detox.

Case 2: 37 year-old female is sent from hospital to an inpatient treatment facility where she spends > 30 days followed up by a residential program.

Learning Objectives

1. Describe the clinical effects of7-OH-mytraginine and how it compares to Kratom

2. List one new adulterant showing up in the nonpharmaceutical heroin/fentanyl supply and describe at least two particular concerns related to this adulterant

About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.

This webinar is free and open to the public.

Donna Papsun, MS, D-ABFT-FT

Forensic Toxicologist & Business Scientist

NMS Labs

Donna Papsun is a forensic toxicologist and business scientist with NMS Labs in Horsham, PA. She has dual Bachelor of Science degrees in Chemistry and Forensic & Investigative Science and a Master of Science degree in Pharmacology. She is also certified as a Diplomate in Forensic Toxicology through the American Board of Forensic Toxicology and is a member of both the Society of Forensic Toxicologists (SOFT) and the American Academy of Forensic Sciences (AAFS).

Ms. Papsun has been with NMS Labs since 2008, first as a bench analyst before promotion to toxicologist in 2012. Ms. Papsun’s main area of interest is novel psychoactive substances or NPS. As one of the two leaders of NMS’s NPS strategy team, she continuously works to help maintain NMS’s leadership in identifying the newest trends in the changing landscape of the designer drug market and developing tests for their detection in forensic toxicology casework. Ms. Papsun also serves in a secondary role as a business scientist, working to align the technical and scientific expertise of NMS Labs with commercial efforts.